Changeflow GovPing Pharma & Drug Safety EPO Patent Publication: Oral Therapeutic Compou...
Routine Rule Added Final

EPO Patent Publication: Oral Therapeutic Compounds Inhibiting HMG-CoA Reductase

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Published March 18th, 2026
Detected March 25th, 2026
Email

Summary

The European Patent Office has published patent application EP4709402A1 for oral therapeutic compounds designed to inhibit HMG-CoA reductase enzyme activity. The application lists Difass International S.p.A. as the applicant.

What changed

This document is a publication of a European patent application (EP4709402A1) related to compositions for oral use that inhibit HMG-CoA reductase enzyme activity. The applicant is Difass International S.p.A. This publication represents the granting of a patent, which provides exclusive rights for the invention.

While this is a patent publication and not a regulatory rule imposing direct compliance obligations on companies, it is relevant for pharmaceutical and biotechnology companies operating in the EU. Companies involved in the development or commercialization of HMG-CoA reductase inhibitors should be aware of this patent to assess potential intellectual property conflicts and market exclusivity.

Source document (simplified)

← EPO Patent Bulletin

COMPOSITIONS FOR ORAL USE WITH HMG-COA REDUCTASE ENZYME INHIBITING ACTIVITY

Publication EP4709402A1 Kind: A1 Mar 18, 2026

Applicants

Difass International S.p.A.

Inventors

AGOSTINI, Alida, BENVENUTI, Francesca, GIORGINI, Davide

IPC Classifications

A61K 36/63 20060101AFI20241115BHEP A61K 36/53 20060101ALI20241115BHEP A61K 36/06 20060101ALI20241115BHEP A61K 31/047 20060101ALI20241115BHEP A61K 36/82 20060101ALI20241115BHEP A61K 31/05 20060101ALI20241115BHEP A61K 31/115 20060101ALI20241115BHEP A61K 31/122 20060101ALI20241115BHEP A61K 31/355 20060101ALI20241115BHEP A61K 31/4045 20060101ALI20241115BHEP A61K 31/714 20060101ALI20241115BHEP A61K 33/06 20060101ALI20241115BHEP A61P 3/06 20060101ALI20241115BHEP A61K 9/20 20060101ALI20241115BHEP A61K 36/02 20060101ALI20241115BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

COMPOSITIONS FOR ORAL USE WITH HMG-COA REDUCTASE ENZYME INHIBITING ACTIVITY

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Rule
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4709402A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Development Intellectual Property
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11
Topics
Drug Development Intellectual Property

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.